CEVHAP. Viral hepatitis. Fast facts. cevhap.org. Accessed December 29, 2021.
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016.
Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. coronavirus.jhu.edu/map.html. Accessed December 29, 2021.
Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31-36.
Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688.
Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567-577.
Li Y, Regan J, Fajnzylber J, et al. Liver fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun. 2021;5:434-445.
Webb G, Marjot T, Cook J, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:P1008-1016.
Rabiee A, Sadowski B, Adeniji N, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience. Hepatology. 2020;72:1900-1911.
Colmenero J, Rodriguez-Peralvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148-155.
Saviano A, Wrensch F, Ghany M, Baumert T. Liver disease and coronavirus disease 2019: from pathogenesis to clinical care. Hepatology. 2021;74:1088-1100.
American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. aasld.org/about-aasld/covid-19-and-liver#consensus-statement. Accessed December 29, 2021.
US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised. Accessed December 29, 2021.
Centers for Disease Control and Prevention. CDC expands eligibility for COVID-19 booster shots to all adults. cdc.gov/media/releases/2021/s1119-booster-shots.html. Accessed December 29, 2021.
Boyarsky B, Ou M, Greenberg R, et al. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105:e56-e57.
Boyarsky B, Werbel W, Avery R, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients JAMA. 2021;325:1784-1786.
Boyarsky B, Werbel W, Avery R, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204-2206.
American Association for the Study of Liver Diseases. AASLD expert panel consensus statement: vaccines to prevent COVID-19 in patients with liver disease. aasld.org/sites/default/files/2021-08/AASLD%20COVID-19%20Vaccine%20Document%20Update%208.30.2021.pdf. Accessed December 29, 2021.
Nouri S, Khoong E, Lyles C, et al. Addressing equity in telemedicine for chronic disease management during the COVID-19 pandemic. catalyst.nejm.org/doi/full/10.1056/CAT.20.0123. Accessed December 29, 2021.
Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infections by primary care providers. N Engl J Med. 2011;364:2199-2207.
Project ECHO. How ECHO is making a difference. hsc.unm.edu/echo. Accessed December 29, 2021.